Atrial Fibrillation - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights

• The rising prevalence of atrial fibrillation is driven by several key factors, including an aging population, which is the strongest predictor of atrial fibrillation, and longer life expectancy among individuals with chronic conditions like heart failure and hypertension. Additionally, poor lifestyle habits, such as obesity, physical inactivity, and excessive alcohol use, along with improved detection and diagnosis, have contributed to the growing number of atrial fibrillation cases.
• Currently, RAPIBLYK (landiolol) is the only FDA-approved ultra-short-acting beta-blocker specifically for rapid heart rate control in atrial fibrillation and atrial flutter in critical care. This limited approval highlights a significant market opportunity for new therapies that can expand treatment options and address unmet needs in atrial fibrillation management.
• Several leading pharmaceutical companies, including Novartis, HUYABIO International, Bristol Myers Squibb, and Johnson & Johnson, are actively advancing their pipelines for the treatment of atrial fibrillation. These efforts reflect a growing focus on developing innovative therapies - such as Factor XIa inhibitors and monoclonal antibodies - to address unmet clinical needs, improve patient outcomes, and reduce the risks associated with current anticoagulant treatments.
• Novartis is expected to pursue regulatory filing for abelacimab in 2027, following the completion of ongoing Phase III trials. This timeline aligns with the company’s strategic focus on advancing innovative anticoagulant therapies for atrial fibrillation and other thromboembolic conditions.
• Many cases of atrial fibrillation go unnoticed, especially when symptoms are mild or intermittent, making timely detection challenging. Limited access to continuous and accurate monitoring often means the condition is discovered only after complications like stroke occur, highlighting gaps in early identification.

The comprehensive report titled “Atrial Fibrillation - Market Insights, Epidemiology, and Market Forecast - 2034” offers a detailed analysis of atrial fibrillation. The report presents historical and projected epidemiological data covering prevalent cases of atrial fibrillation, diagnosed prevalent cases of atrial fibrillation, gender-specific diagnosed prevalent cases of atrial fibrillation, and age-specific diagnosed prevalent cases of atrial fibrillation. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in atrial fibrillation. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Atrial Fibrillation Overview

Atrial fibrillation is the most common form of cardiac arrhythmia, caused by abnormal electrical impulses in the atria that lead to rapid and irregular heartbeats. Classified as a tachyarrhythmia, atrial fibrillation can be paroxysmal (lasting less than seven days) or persistent (lasting more than seven days). The irregular rhythm disrupts normal blood flow, increasing the risk of thrombus (blood clot) formation, which can travel to the brain and cause a stroke - making atrial fibrillation the leading cardiac-related cause of stroke. Risk factors include advanced age, hypertension, structural heart or lung disease, congenital heart defects, and excessive alcohol intake. Symptoms range from none to chest pain, palpitations, rapid heartbeat, shortness of breath, dizziness, nausea, sweating, and fatigue. While atrial fibrillation can become a chronic condition, several treatment and risk-reduction strategies exist. These include anticoagulants, medications for rate and rhythm control, electrical cardioversion, catheter ablation, and other interventional cardiac procedures aimed at minimizing stroke risk and improving quality of life.

Atrial Fibrillation Diagnosis and Treatment Overview

The evaluation of atrial fibrillation begins with a thorough history and physical examination to identify risk factors, comorbidities, and clinical signs such as abnormal heart sounds, elevated jugular venous pressure, pulmonary rales, or signs of heart failure. Diagnostic workup includes blood tests - complete blood count, electrolytes, thyroid function, liver and kidney panels - and imaging studies like echocardiography and chest X-rays to assess cardiac and pulmonary status.

Treatment focuses on three pillars: rate control, rhythm control, and anticoagulation. The choice between rhythm and rate control depends on symptom severity, comorbidities, and the likelihood of successful cardioversion or ablation. Warfarin remains a key anticoagulant for patients at moderate to high risk of thromboembolism, though not all patients are eligible due to contraindications. Antiarrhythmic drugs such as flecainide, sotalol, dofetilide, and off-label agents like amiodarone aim to reduce atrial fibrillation episodes and improve quality of life, potentially reducing the need for long-term anticoagulation in select cases.

Atrial Fibrillation Epidemiology

The epidemiology section of the atrial fibrillation market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of atrial fibrillation. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• According to recent secondary analyses, the estimated prevalence of atrial fibrillation in the United States ranges from approximately 2.7 to 6.1 million individuals.
• According to 2024 data from the National Heart, Lung, and Blood Institute (NHLBI), researchers found that approximately 2 million adults - representing 6.8% of the population studied - had atrial fibrillation, an irregular heart rhythm.
• In US, Atrial fibrillation prevalence increases significantly with age: it affects just 0.1% of individuals under 55, rises to 3.8% among those aged 60 and older, and reaches approximately 10% in people aged 80 and above. This age-related trend underscores the strong correlation between advancing age and atrial fibrillation risk.
• Secondary analysis indicates that atrial fibrillation is highly prevalent in the US, with an estimated lifetime risk of developing the condition affecting approximately 1 in 3 individuals over the age of 45.
• Recent secondary analysis indicates that approximately 1 in every 45 individuals in the UK is currently living with atrial fibrillation, highlighting its growing prevalence and public health impact.
• Epidemiological data from Japan reveal a higher prevalence of atrial fibrillation in men compared to women across all age groups. When stratified by decade, atrial fibrillation prevalence in men was 0.3% (ages 50-59), 2.4% (60-69), and 4.1% (70-79). In contrast, prevalence among women in the same age brackets was significantly lower at 0%, 0.3%, and 0.7%, respectively. These findings underscore a pronounced sex-based disparity in atrial fibrillation risk, particularly with advancing age.

Atrial Fibrillation Market Outlook

The atrial fibrillation therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

The treatment landscape for atrial fibrillation includes a variety of pharmacologic and interventional strategies aimed at stroke prevention, heart rate control, and rhythm management. Standard therapies involve anticoagulants such as apixaban and warfarin, beta-blockers like metoprolol, and antiarrhythmics including amiodarone. In critical care settings, the recent FDA approval of RAPIBLYK (landiolol) has introduced a new option for rapid, short-term heart rate control in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. RAPIBLYK, an ultra-short-acting beta-1 selective blocker, demonstrated heart rate reduction in 40-90% of patients within 10 minutes, with minimal impact on blood pressure. This approval marks a significant advancement in acute atrial fibrillation management, particularly for patients requiring immediate intervention in intensive care environments.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to the publisher, the atrial fibrillation market in the 7MM is expected to change significantly during the forecast period (2025-2034).

Atrial Fibrillation Drug Chapters

Marketed Drugs

RAPIBLYK (landiolol): AOP Orphan Pharmaceuticals

Landiolol is an ultra-short-acting beta-adrenergic receptor antagonist with a high beta-1 to beta-2 selectivity ratio of 255. It offers a rapid onset of action and effectively lowers heart rate with minimal impact on blood pressure. Primarily intended for acute care settings - such as emergency departments, cardiac critical care units, operating rooms, and intensive care - it is used for short-term management rather than chronic treatment of cardiac arrhythmias.

• In Europe, landiolol is marketed as RAPIBLOC and approved to treat supraventricular tachycardia, including atrial fibrillation and atrial flutter. In Japan, the same drug is available under the brand name ONOACT, developed and distributed by Ono Pharmaceutical.
• In November 2024, AOP Health reported that the US FDA granted regulatory approval for RAPIBLYK (landiolol) for use in hospital critical care settings. This approval covers the short-term treatment of supraventricular tachycardia, including atrial fibrillation, offering a rapid-acting option for heart rate control with minimal impact on blood pressure.
• The FDA’s approval of RAPIBLYK (landiolol) was based on data from five randomized, double-blind, placebo-controlled trials involving 317 adults with supraventricular tachycardia. Landiolol demonstrated rapid efficacy, reducing heart rate in 40-90% of patients within about 10 minutes, compared to just 0-11% in the placebo group.

Emerging Drugs

Milvexian: Bristol Myers Squibb/ Johnson & Johnson

Milvexian is an investigational oral anticoagulant developed by Bristol Myers Squibb in collaboration with Janssen, designed specifically as a selective inhibitor of Factor XIa, a key enzyme in the intrinsic coagulation pathway. Milvexian is currently being evaluated in the large Phase III LIBREXIA-AF trial, a global, randomized, double-blind study comparing its efficacy and safety to apixaban.

• Phase III data from the LIBREXIA-AF trial, evaluating milvexian for atrial fibrillation, is anticipated by 2027. This trial is part of the broader LIBREXIA program, one of the most comprehensive clinical efforts targeting factor XIa inhibition for thromboembolic risk reduction.
• In May 2023, Bristol Myers Squibb, in collaboration with Janssen Pharmaceuticals, announced that the US FDA had granted Fast Track Designation (FTD) for all three of milvexian’s investigational indications, including atrial fibrillation.

Abelacimab: Novartis

Abelacimab is a novel investigational therapy - a fully human, highly selective monoclonal antibody - that binds tightly to Factor XI, effectively blocking its activation and preventing the formation of its active form, Factor XIa. By doing so, it mimics the protective effect seen in individuals with natural Factor XI deficiency, which is associated with a reduced risk of thromboembolic events. It has received FTD for the prevention of stroke and systemic embolism in patients with atrial fibrillation from US FDA.

• Currently, Abelacimab is being investigated in Phase III for the treatment of Atrial Fibrillation.
• In February 2025, Novartis reported an agreement to acquire Anthos Therapeutics, a clinical-stage biopharmaceutical company developing abelacimab, a late-stage investigational therapy, being evaluated for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
• In June 2023, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) granted approval to launch the Phase III LILAC-TIMI 76 trial, evaluating abelacimab in atrial fibrillation patients considered unsuitable for currently available anticoagulants.

HBI-3000: HUYABIO International

HBI-3000, a multi-ion channel blocker developed by HUYABIO International, exhibits in vitro inhibition of INa-Peak, INa-Late, ICa-L, and IKr. It is being evaluated for the conversion of recent-onset atrial fibrillation. Both preclinical and clinical pharmacology data indicate its potential to restore sinus rhythm, with preclinical studies showing a low risk of proarrhythmia.

• Currently, HBI-3000 is in Phase II for the treatment of atrial fibrillation.
• In April 2025, HUYABIO International unveiled new patient data on HBI-3000 demonstrating strong antiarrhythmic potential, excellent tolerability, and a distinctive mechanism that minimizes QT prolongation and reduces the likelihood of life-threatening arrhythmias. These initial safety and efficacy findings were showcased in a poster presentation at the Heart Rhythm Annual Meeting held that month.
• In November 2024, HUYABIO International disclosed new patient-level data highlighting the clinical potential of HBI-3000, an antiarrhythmic agent characterized by a distinctive protective pharmacological profile.

Atrial Fibrillation Market Segmentation

The ‘Atrial Fibrillation- Market Insights, Epidemiology, and Market Forecast - 2034’ report provides a detailed outlook of the current and future atrial fibrillation market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Atrial Fibrillation Market Size by Countries

The atrial fibrillation market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM atrial fibrillation market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Atrial Fibrillation Drugs Uptake

This section focuses on the sales uptake of potential atrial fibrillation drugs that have recently been launched or are anticipated to be launched in the atrial fibrillation market between 2020 and 2034. It estimates the market penetration of atrial fibrillation drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the atrial fibrillation market.

The emerging atrial fibrillation therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the atrial fibrillation market.

Atrial Fibrillation Market Access and Reimbursement

The ‘Atrial Fibrillation - Market Insights, Epidemiology, and Market Forecast - 2034’ report provides a descriptive overview of the market access and reimbursement scenario of atrial fibrillation. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current atrial fibrillation market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the atrial fibrillation domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or atrial fibrillation market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the atrial fibrillation unmet needs.

Atrial Fibrillation: KOL Insights

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as, Boston University School of Public Health, Boston, US, Femme Mère Enfant Hospital, Lyon, France; University Medical Center Mainz, Germany; Department of Internal Medicine, Eifelklinik St. Brigida, Simmerath, Germany; Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Tokyo Women’s Medical University School of Medicine, Tokyo, Japan among others.

"Abelacimab is regarded as a potential first-in-class medicine, offering a promising and potentially safer alternative to current standards of care for preventing thrombosis and stroke. Its origin at Novartis is a point of pride, and the expertise and dedication demonstrated by the Anthos Therapeutics team have been highly regarded, along with the significant progress made in the program. The decision has now been made to reintegrate abelacimab into the Novartis cardiovascular, renal, and metabolic (CRM) pipeline at this pivotal stage."

"Cardiac remodeling, particularly of atria, results in structural and electrical changes that eventually become the cause of deranged rhythm in atrial fibrillation. Structural remodeling is caused by the changes in myocytes and the extracellular matrix, and fibrous tissue deposition also plays a major role in some etiologies. On the other hand, tachycardia and shortening of the refractory period lead to electrical remodeling."

"Atrial fibrillation is diagnosed through ECG, revealing irregular, rapid heart rhythms. Symptoms like palpitations, fatigue, and shortness of breath prompt evaluation. Holter monitoring, echocardiography, and blood tests help assess heart function and rule out underlying causes. Timely diagnosis is vital to prevent stroke and manage long-term cardiovascular risks effectively.”

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the atrial fibrillation. Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Atrial Fibrillation Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for atrial fibrillation. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging atrial fibrillation therapies.

Atrial Fibrillation Report Insights

• Atrial Fibrillation Patient Population
• Therapeutic Approaches
• Atrial Fibrillation Pipeline Analysis
• Atrial Fibrillation Market Size and Trends
• Atrial Fibrillation Market Opportunities
• Impact of Upcoming Therapies

Atrial Fibrillation Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Atrial Fibrillation Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Atrial Fibrillation Market
• Atrial Fibrillation Drugs Uptake

Atrial Fibrillation Report Assessment

• Atrial Fibrillation Current Treatment Practices
• Unmet Needs
• Atrial Fibrillation Product Profiles
• Atrial Fibrillation Market Attractiveness

Key Questions

• How common is atrial fibrillation?
• What are the key findings of atrial fibrillation epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for atrial fibrillation?
• What are the disease risk, burden, and unmet needs of atrial fibrillation?
• At what CAGR is the atrial fibrillation market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the atrial fibrillation market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of atrial fibrillation in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of atrial fibrillation?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the atrial fibrillation market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of Market Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.